|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,163,904: Tofacitinib Citrate Composition and Manufacturing
This report analyzes U.S. Patent 8,163,904, titled "Tofacitinib citrate," focusing on its claims, scope, and the broader patent landscape surrounding the drug tofacitinib citrate. The patent, granted on April 24, 2012, to Pfizer Inc., covers specific crystalline forms of tofacitinib citrate and methods for their preparation. Tofacitinib, marketed as Xeljanz and Xeljanz XR, is a Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
What Are the Core Inventions Claimed by U.S. Patent 8,163,904?
The patent primarily claims specific crystalline forms of tofacitinib citrate. These forms are characterized by their distinct X-ray powder diffraction (XRPD) patterns and other physical properties.
What Crystalline Forms Are Protected?
U.S. Patent 8,163,904 claims several specific crystalline forms of tofacitinib citrate. The key forms are defined by their XRPD data, which serves as a fingerprint for identifying the crystalline structure.
- Form I: This form is characterized by specific peaks in its XRPD pattern. Key 2-theta diffraction angles at values of approximately 4.8, 9.6, 15.0, 19.2, and 24.1 degrees are cited.
- Form II: This form is also defined by its XRPD pattern, with characteristic peaks at approximately 5.4, 10.7, 15.9, 21.3, and 26.5 degrees 2-theta.
- Form III: This amorphous form is described as lacking substantial peaks in its XRPD pattern.
The patent details the processes for obtaining these specific forms, including crystallization steps from various solvent systems and controlled drying conditions.
What Manufacturing Processes Are Covered?
The patent also claims methods for producing these crystalline forms. These methods involve:
- Crystallizing tofacitinib citrate from a solvent mixture, often including alcohols, ketones, or esters, in the presence of water.
- Controlling crystallization parameters such as temperature, cooling rate, and seeding.
- Drying the resulting crystalline material under specific conditions to maintain the desired polymorphic form.
One critical aspect is the preparation of Form I from a process involving tofacitinib free base and citric acid in a specific solvent system, followed by crystallization. Another claimed process focuses on obtaining Form II, often involving specific solvent ratios and crystallization temperatures.
How Does Patent 8,163,904 Define Tofacitinib Citrate?
The patent defines tofacitinib citrate by its chemical structure and its various crystalline forms.
What Is the Chemical Structure of Tofacitinib?
Tofacitinib is chemically known as 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile. The patent discloses this structure and establishes the salt formed with citric acid.
What Are the Key Physical and Chemical Properties Described?
Beyond XRPD, the patent describes other physical and chemical characteristics of the claimed crystalline forms, such as:
- Differential Scanning Calorimetry (DSC) thermograms: These provide information on thermal transitions, including melting points and decomposition temperatures, which vary between different crystalline forms. For instance, Form I exhibits a specific DSC profile with a particular melting endotherm.
- Thermogravimetric Analysis (TGA): This indicates the presence of residual solvents or water within the crystalline structure.
- Infrared (IR) spectroscopy: This provides further structural identification and confirmation of the crystalline form.
These characterizations are crucial for distinguishing between the claimed polymorphs and other potential forms of tofacitinib citrate.
What Is the Legal Status and Expiration of Patent 8,163,904?
Understanding the patent's legal status and expiration is critical for assessing market entry for generic competitors.
When Was the Patent Granted and When Does It Expire?
U.S. Patent 8,163,904 was granted on April 24, 2012. Barring any extensions or challenges, its standard expiration date would be 20 years from its filing date. The original filing date for this patent application was August 19, 2009. Therefore, its standard expiration date is August 19, 2029.
Are There Any Extensions or Post-Grant Challenges?
Patents for pharmaceutical products are often eligible for Patent Term Extension (PTE) under the Hatch-Waxman Act to compensate for regulatory review delays. As of current public records, it is common for a primary drug patent like this to have undergone or be eligible for PTE. Specific details regarding PTE for U.S. Patent 8,163,904 would need to be verified through the U.S. Patent and Trademark Office (USPTO) database and FDA Orange Book.
Additionally, patents can face post-grant challenges such as inter partes review (IPR) at the USPTO. Such challenges can lead to claims being invalidated or narrowed, significantly impacting the patent's enforceability. Legal databases and dockets of the USPTO and relevant courts would need to be consulted for any ongoing or past challenge proceedings.
What Is the Competitive Patent Landscape for Tofacitinib Citrate?
The patent landscape for tofacitinib citrate is complex, involving not only the primary composition-of-matter patents but also patents covering formulations, methods of use, and manufacturing processes.
What Other Patents Protect Tofacitinib Citrate?
Beyond U.S. Patent 8,163,904, Pfizer holds numerous other patents related to tofacitinib. These can be broadly categorized as:
- Composition of Matter Patents: These would cover the tofacitinib molecule itself. The foundational patents for tofacitinib were likely filed much earlier than Patent 8,163,904.
- Formulation Patents: These protect specific dosage forms, such as extended-release formulations (e.g., Xeljanz XR), tablets, and the excipients used.
- Method of Use Patents: These claims cover the use of tofacitinib to treat specific medical conditions, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. These patents are crucial for defining the therapeutic indications.
- Process Patents: These cover alternative or improved methods of synthesizing tofacitinib or its salts, independent of specific crystalline forms.
- Polymorph Patents: U.S. Patent 8,163,904 is one such patent focused on specific crystalline forms. It is common for companies to file multiple patents for different polymorphs discovered over time, each with distinct properties and manufacturing methods.
The interplay of these various patents dictates the freedom to operate for generic manufacturers.
How Do Other Patents Interact with Patent 8,163,904?
Patent 8,163,904, by protecting specific crystalline forms, adds a layer of complexity. Even if a generic manufacturer can synthesize the tofacitinib molecule and formulate it into a dosage form, they may infringe on this patent if their product utilizes one of the claimed crystalline forms (e.g., Form I or Form II) without a license.
Generic companies often aim to develop a non-infringing crystalline form or process. This might involve identifying and characterizing a new, patentable polymorph, or developing a manufacturing route that bypasses the patented steps for producing the protected forms.
The existence of method-of-use patents is also critical. A generic product must not only avoid infringing composition or form patents but also be launched for indications that are not protected by active method-of-use patents, or for which those patents have expired or been invalidated.
The regulatory approval process in the U.S., managed by the Food and Drug Administration (FDA) through the Orange Book, lists patents associated with approved drug products. Generic applicants must certify their proposed product does not infringe on listed patents or that the patents are invalid.
What Are the Key Infringement Considerations for Generic Manufacturers?
Generic manufacturers must carefully navigate the patent landscape to avoid infringing existing patents.
How Can Generic Manufacturers Avoid Infringing Patent 8,163,904?
To avoid infringing U.S. Patent 8,163,904, a generic manufacturer would need to:
- Develop a Non-Infringing Crystalline Form: This involves identifying or creating a crystalline form of tofacitinib citrate that is not claimed by the patent, and then demonstrating that this new form is stable, bioequivalent, and therapeutically effective. This would require extensive characterization, including XRPD, DSC, and TGA, to prove it is structurally different from Forms I and II.
- Develop a Non-Infringing Manufacturing Process: If the patent claims specific steps in the manufacturing process for Forms I or II, an alternative synthesis route that does not use those patented steps would need to be devised. This could involve different reagents, reaction conditions, or purification methods.
- Formulate the Drug Without Using Claimed Forms: Even if a crystalline form is not directly infringing, if the manufacturing process specified in the patent is used to produce the active pharmaceutical ingredient (API) that is then incorporated into a dosage form, infringement can still occur. The generic manufacturer must ensure their entire production process, from API synthesis to final drug product, does not infringe any claims of the patent.
What Are the Implications of Patent Disputes?
Patent disputes, such as Paragraph IV certifications under the Hatch-Waxman Act, can lead to litigation. If a generic manufacturer files a Paragraph IV certification, challenging the validity or non-infringement of a patent, the brand-name manufacturer may sue.
- Automatic 30-Month Stay: In some cases, filing a patent infringement suit after a Paragraph IV certification can trigger a 30-month stay on FDA approval of the generic drug. This provides time for the patent litigation to be resolved.
- Litigation Outcomes: The outcome of litigation can significantly impact market entry. If the patent is found to be valid and infringed, the generic drug's approval will be delayed. Conversely, if the patent is invalidated or found not to be infringed, the generic manufacturer may be able to launch their product sooner.
- Damages: If infringement is found, the infringing party may be liable for damages.
The analysis of U.S. Patent 8,163,904's claims and scope, in conjunction with other relevant patents, is a critical step for any entity considering the development or marketing of a generic version of tofacitinib citrate.
Key Takeaways
- U.S. Patent 8,163,904 protects specific crystalline forms of tofacitinib citrate, notably Forms I and II, and methods for their production, expiring in August 2029.
- The patent defines these forms by their unique X-ray powder diffraction patterns and other physical characteristics.
- Generic manufacturers must develop non-infringing crystalline forms or manufacturing processes to enter the market for tofacitinib citrate.
- The broader patent landscape, including composition-of-matter, formulation, and method-of-use patents, must be analyzed comprehensively alongside Patent 8,163,904.
- Patent litigation, particularly Paragraph IV challenges, plays a significant role in determining generic market entry timelines.
FAQs
-
What is the primary focus of U.S. Patent 8,163,904?
The patent primarily protects specific crystalline forms of tofacitinib citrate, identified as Form I and Form II, along with methods for their manufacture.
-
When does U.S. Patent 8,163,904 expire?
The standard expiration date for U.S. Patent 8,163,904 is August 19, 2029, reflecting its filing date of August 19, 2009, and a 20-year term.
-
Can generic manufacturers use the exact crystalline forms protected by Patent 8,163,904?
Generic manufacturers generally cannot use the specific crystalline forms (Form I and Form II) claimed by Patent 8,163,904 unless they obtain a license or the patent is invalidated, as their use would likely constitute infringement.
-
Besides crystalline forms, what other types of patents protect tofacitinib citrate?
The patent landscape for tofacitinib citrate includes patents covering the tofacitinib molecule itself (composition of matter), specific dosage formulations (e.g., extended-release), methods of treating various diseases, and alternative manufacturing processes.
-
What is a key challenge for generic companies regarding this patent?
A key challenge is developing a crystalline form of tofacitinib citrate that is not claimed by Patent 8,163,904 or devising a manufacturing process that avoids infringing the patented methods, while also ensuring bioequivalence and therapeutic efficacy.
Citations
[1] U.S. Patent No. 8,163,904 (filed Aug. 19, 2009; issued Apr. 24, 2012).
More… ↓
⤷ Get Started Free
|
